Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

Investigational New Drugs

Volumn 24, Issue 1, 2006, Pages 85-88

  Vuky, Jacqueline ^a,d   Isacson, Christina ^b   Fotoohi, Mehran ^c   Dela Cruz, Jason ^d   Otero, Henry ^d   Picozzi, Vincent ^d   Malpass, Thomas ^a   Aboulafia, David ^a   Jacobs, Andrew ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Section of Radiology   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Imatinib (Gleevec ); Metastatic renal cell carcinoma; Phase II trial

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; DRUG FEVER; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGICAL PARAMETERS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY FUNCTION; LIFE EXPECTANCY; LIVER FUNCTION; MALE; METASTASIS; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 31544474604     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-4543-z     Document Type: Article

References (9)

1. Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. Lyon, IARCPress, 2001. Limited version available from: URL: http://www-dep.iarc.fr/ globocan/globocan.html. Last updated on 03/02/2001
2. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335(19):865-875, 1996
3. Motzer RJ, Vogelzang NG: Chemotherapy for renal cell carcinoma. In: Raghaven D, Scher HI, Leibel SA, Lange P (eds) Principles and Practice of Genitourinary Oncology. Lippincott-Raven, Philadelphia, 1997 pp 885-896
4. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002
5. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
6. Karikehalli S, Kallakury BVS, Sheehan CE, Bratslavsky G, Kaufman RP, Fisher HAG, Ross, JS. Patterns of c-kit proto-oncogene product expression in renal cell carcinoma (RCC): co-expression with stem cell factor (SCF) and correlation with high grade malignancy (Abstract) J Urol supp 104A:603, 2000
7. Ramp U, Jaquet K, Reinecke P, Schardt C, Friebe U, Nitsch T, Marx N, Gabbert HE, Gerharz CD: Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. J Urol 157:2345-2350, 1997
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
9. Remmele W, Schicketanx K-H: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer: computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Path Res Pract 189:862-866, 1993